# Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

> **NCT05858736** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **OncoC4, Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Melanoma
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- High Grade Serous Adenocarcinoma of Ovary
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Endometrial Cancer
- Cervical Cancer
- Renal Cell Carcinoma
- Bladder Cancer
- Esophageal Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Colorectal Cancer
- Anal Cancer
- Hepatocellular Carcinoma
- Bile Duct Cancer

## Interventions

- **DRUG:** AI-061

## Key facts

- **NCT ID:** NCT05858736
- **Lead sponsor:** OncoC4, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-11
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05858736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05858736, "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05858736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*